152 related articles for article (PubMed ID: 24796142)
1. [Programs for continuing medical education: B session 7. Progress in treatment for hematologic diseases].
Higashihara M
Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):717-23. PubMed ID: 24796142
[No Abstract] [Full Text] [Related]
2. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Kantarjian HM; Cortes JE; Rowe JM; Kurzrock R
Semin Hematol; 2002 Jul; 39(3 Suppl 2):36-8. PubMed ID: 12214292
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
4. A summer of hematologic science. Highlights from the 45th Annual Meeting of the American Society of Clinical Oncology, the 14th Congress of the European Hematology Association, and the 2009 Pan Pacific Lymphoma Conference.
Cheson BD; Ashforth E
Clin Adv Hematol Oncol; 2009 Sep; 7(9 Suppl 15):1-22; quiz 23-4. PubMed ID: 20102012
[No Abstract] [Full Text] [Related]
5. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1999; 18():268-92. PubMed ID: 10800488
[No Abstract] [Full Text] [Related]
6. Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia.
Ping N; Wang Q; Wang Q; Dong S; Wu L; Xue Y; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2012 Dec; 53(12):2498-9. PubMed ID: 22639828
[No Abstract] [Full Text] [Related]
7. [Current status and future perspective of new drugs for hematological malignancies in Japan].
Ogura M
Rinsho Ketsueki; 2007 Oct; 48(10):1442-52. PubMed ID: 17933133
[No Abstract] [Full Text] [Related]
8. Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment.
San-Miguel JF; Kantarjian HM
Nat Rev Clin Oncol; 2015 Feb; 12(2):71-2. PubMed ID: 25511190
[TBL] [Abstract][Full Text] [Related]
9. [Current status in and future directions of the treatment of hematological disorders with molecular-targeting agents--Overview].
Kizaki M
Rinsho Ketsueki; 2011 Aug; 52(8):583-6. PubMed ID: 21897063
[No Abstract] [Full Text] [Related]
10. Targeted therapy for hematologic malignancies.
Kuriakose P
Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
[TBL] [Abstract][Full Text] [Related]
11. [Hematological malignancies].
Usui N
Gan To Kagaku Ryoho; 2007 Mar; 34(3):358-66. PubMed ID: 17353625
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.
Pagano L; Fianchi L; Mele L; Girmenia C; Offidani M; Ricci P; Mitra ME; Picardi M; Caramatti C; Piccaluga P; Nosari A; Buelli M; Allione B; Cortelezzi A; Fabbiano F; Milone G; Invernizzi R; Martino B; Masini L; Todeschini G; Cappucci MA; Russo D; Corvatta L; Martino P; Del Favero A
Br J Haematol; 2002 May; 117(2):379-86. PubMed ID: 11972521
[TBL] [Abstract][Full Text] [Related]
13. Counterpoint: Data first.
Golub T
Nature; 2010 Apr; 464(7289):679. PubMed ID: 20360719
[No Abstract] [Full Text] [Related]
14. Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M
Leuk Res; 2004 May; 28(5):443-6. PubMed ID: 15068895
[No Abstract] [Full Text] [Related]
15. [Development of molecular targeted therapy for hematological disorder in the era of genomic drug discovery].
Yoshimi A; Kurokawa M
Nihon Rinsho; 2014 Jun; 72(6):1005-11. PubMed ID: 25016796
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the power of antisense technology for combination chemotherapy.
Narayanan R
J Natl Cancer Inst; 1997 Jan; 89(2):107-8. PubMed ID: 8998173
[No Abstract] [Full Text] [Related]
17. The promise of gene expression analysis in hematopoetic malignancies.
Radich JP
Biochim Biophys Acta; 2002 Mar; 1602(1):88-95. PubMed ID: 11960697
[No Abstract] [Full Text] [Related]
18. European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.
Rack KA; van den Berg E; Haferlach C; Beverloo HB; Costa D; Espinet B; Foot N; Jeffries S; Martin K; O'Connor S; Schoumans J; Talley P; Telford N; Stioui S; Zemanova Z; Hastings RJ
Leukemia; 2019 Aug; 33(8):1851-1867. PubMed ID: 30696948
[TBL] [Abstract][Full Text] [Related]
19. Molecular cytogenetic aspects of hematological malignancies: clinical implications.
Chen Z; Sandberg AA
Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
Imashuku S; Morimoto A; Kuriyama K; Kano G; Hibi S; Todo S
Med Pediatr Oncol; 2003 Aug; 41(2):159-60. PubMed ID: 12825226
[No Abstract] [Full Text] [Related]
[Next] [New Search]
